Opportunities, controversies, and challenges of extracorporeal hemoadsorption with CytoSorb during ECMO.
Artif Organs
; 45(10): 1240-1249, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1354462
ABSTRACT
Extracorporeal membrane oxygenation (ECMO) is frequently used in many centers around the globe for various indications. However, prognosis is often poor even with all supportive therapies, and in many cases, clinical deterioration is associated with inflammation. Hemoadsorption with CytoSorb is a novel approach to limit the inflammatory response, and the device can be safely and easily installed into ECMO circuits. CytoSorb has been used more than 130.000 times to date, but because randomized controlled trials are largely lacking, there is substantial debate on its use. Here, experts from critical care medicine, cardiology, cardiac surgery, and perfusion technology discuss the pros and cons of this novel therapy and outline the future aspects for its clinical application and research.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Extracorporeal Membrane Oxygenation
/
Hemofiltration
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Artif Organs
Year:
2021
Document Type:
Article
Affiliation country:
Aor.14025
Similar
MEDLINE
...
LILACS
LIS